John Simard

John Simard

john simard is the founder and CEO of XBiotech, a clinical-stage biopharmaceutical company. The company is engaged in developing True Human (antibody technology) monoclonal antibodies for the treatment of a variety of diseases.

Simard has more than 140 issued and pending patents related to cancer therapy, therapeutic vaccines and therapeutic antibodies. He is also the author of several peer-reviewed scientific publications and a textbook Immune Response Genes.

Early Life and Education

John Simard grew up in Philadelphia, Pennsylvania. He spent summers on his aunt and uncle’s farm where he helped them to grow their own food.

He later attended a number of schools. He had little patience for schooling and often struggled with his studies.

After college, he decided to study law. He wanted to become a prominent lawyer and had the ambition of fame and recognition.

He was influenced by the eighteenth-century Enlightenment and had heard that the legal profession was more reputable than the clergy. However, he did not want to relinquish his Puritan ethics for the sake of a lucrative career.

Professional Career

John Simard is the founder, chairman and CEO of XBiotech Inc (XBIT) in Austin, Texas. He holds over 300 issued and pending patents related to cancer therapy, therapeutic vaccines and monoclonal antibody manufacturing.

During his professional career, he has won numerous awards and accolades. Some of the most prestigious include being named the Florida Division Professional of the Year and USPTA Player of the Year in 2010.

He also serves on the board of directors for a handful of companies. He is a member of the American Society for Biochemistry and Molecular Biology, and has been nominated as an associate of the National Institutes of Health. He is a frequent speaker at industry conferences and has been featured in several publications. The most important thing he has learned over the years is that family and friends are the most important people in his life.

Achievements and Honors

Founder, President, CEO & Chairman at XBiotech USA, John Simard is a jack of all trades when it comes to his company. He has over 300 issued and pending patents and has made a splash in the research & development industry as one of its most successful and innovative executives. Currently, he is working on a multi-instrument airborne remote sensing project which will help in the quest to understand how high-frequency hydrological and sediment transport processes contribute to ecosystem productivity and the resilience of river deltas in the face of climate change.

He is also a stoutly devoted conservationist and holds a master’s degree in wildlife science. When he’s not hard at work on his latest project, you can find him enjoying Vermont’s great outdoors, including hunting and fishing, tying flies or reading a book.

Personal Life

Having forged a remarkable career as an ecologist and immunologist, John Simard’s personal life is a tale of persistence, determination and resilience. Her evocative memoir, Finding the Mother Tree, details her journey from earth-eating child to scientist.

From her family’s forestry career in Canada to her research on Mother Trees, she chronicles her friendships and relationships, marriage and motherhood, as well as her battle against breast cancer. The realism of her accounts – the nine-hour commute to and from labs, the struggle to be taken seriously in a forestry culture dominated by men – is no doubt what lifted her work above that of the many popular science books on the market.

John Simard is currently Chairman of the Board, President, Chief Executive Officer and Founder at XBiotech Inc. As of 15 October 2021, he had a net worth of $32.3 million.

Net Worth

John Simard has an estimated net worth of $32.3 Million. He is currently Chairman of the Board, President, Chief Executive Officer and Founder at XBiotech Inc. XBiotech is an innovative biotechnology company that develops and markets therapeutic products for cancer, infectious diseases, and autoimmune disorders. Founded in 2005, the Company is focused on the discovery and development of cellular and antibody therapeutics for cancer, and has received over 300 issued and pending patents for their methods and compositions.

According to his Form 4 filed with the SEC, John has made a total of 10 trades of XBiotech stock since 2016. The largest of these was exercising 500,000 units of XBIT stock on 22 March 2021 for over $3,750,000. Get notified when John Simard buys or sells XBiotech stock.

Leave a Reply

Your email address will not be published. Required fields are marked *